Skip to main content
Resources & Evidence Contact us

Corporate profile

Established in 1999, Prolacta Bioscience is a privately held life sciences company that has touched the lives of more than 100,000 premature infants globally.1

Available in hospitals since 2006, our 100% human milk-based fortifiers changed the standard of care for extremely premature infants worldwide. These are the first nutritional fortifiers made from 100% donor human milk instead of cow milk.

Expanding globally

Our line of human milk-based fortifiers is currently on the market in 9 countries. Most recently, our fortifier for infants recovering from cardiovascular surgeries became available in Germany and Austria. We are also continuing our efforts to bring our products to more patients throughout Europe and the rest of the world.

Future innovations

In addition to exploring innovations and product line extensions for our core nutrition business, we are actively considering business development opportunities. Further, our promising orphan drug pipeline is focused on finding new innovative therapies for indications with highly unmet needs such as Allo-HCT, solid organ transplantation, among others.

Meet our leadership team

People dedicated to living up to our mission and improving the lives of babies

Learn about our impact beyond patients

We work to protect our environment, contribute to society, and operate ethically

Learn how we ensure safety

We lead the human milk industry in the steps we take to ensure quality and safety

Press + news

See all
  • Press releases
  • Prolacta in the news

Prolacta Bioscience neonatologist Dr. Erin Hamilton Spence earns breastfeeding and lactation medicine certification held by fewer than 100 North American physicians

FDA approves first human milk-based fortifier for term infants to support growth and recovery following surgery for Gastroschisis

Study finds fewer cases of Necrotizing Enterocolitis in premature infants and cost savings after implementing an Exclusive Human Milk Diet

Study shows vat pasteurization outperforms other methods in preserving human milk’s native bioactive properties

Hot Topics in Neonatology® 2024 Conference to feature symposium on clinical impact & cost savings of an Exclusive Human Milk Diet

Prolacta celebrates advancements in neonatal care during Prematurity Awareness Month

Humavant® 100% human milk-based fortifiers helping premature infants in Australia grow and develop

Prolacta Bioscience appoints Dr. Sandra Sullivan as director of clinical education and professional development

Prolacta Bioscience applauds passage of New York legislation expanding insurance coverage for human milk-based nutritional products

Prolacta Bioscience applauds new California state law expanding access to donor human milk for fragile infants

More than 50% of level III & IV NICUs in U.S. used Prolacta's 100% human milk-based products to help reduce Necrotizing Enterocolitis (NEC) in the smallest premature infants in 2024

Prolacta Bioscience applauds passage of the maternal health bill in Massachusetts

Working to address equity in premature nutrition, National Black Nurses Association and Prolacta Bioscience support H.R. 7141

Preterm infant study finds proactive use of Prolact CR cream improves growth and reduces NICU costs

Prolacta Bioscience demonstrates leadership in human milk science with history of voluntarily reviewing health claims with the FDA

Study shows exclusive human milk diet benefits term infants post-gastroschisis repair; Data to be presented at ESPGHAN 2024 meeting

Pediatric Academic Societies Meeting includes symposium on cost-effectiveness of implementing exclusive human milk-based nutrition for premature infants

Novel research illuminates breast milk’s unique contribution to COVID-19 defense in infants

Real-world data on human milk-based fortification reveals limitations of protocol designs of two RCTs

Prolacta's human milk-based nutrition has touched the lives of 100,000 Premature and Critically Ill Infants Globally

Prolacta Bioscience recognizes advances in preterm care during NICU awareness month

New study shows Prolacta’s human milk-based nutritional fortifiers save hospital NICUs up to $3.4M annually

Prolacta Bioscience applauds Ohio legislature for supporting Medicaid reimbursement for donor human milk-derived products

Study reveals Prolacta’s 100% human milk-based nutritional fortifiers significantly increase bioactive proteins and antioxidant activity in human milk samples, outperforming cow milk-based fortifier

Prolacta Bioscience celebrates donor moms on World Human Milk Donation Day

Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month

Upcoming events

All events

Citations